SPL 9.20% 9.5¢ starpharma holdings limited

Surely DEP-Cabazitaxel would be the perfect drug for Sandoz, who...

  1. 90 Posts.
    lightbulb Created with Sketch. 67
    Surely DEP-Cabazitaxel would be the perfect drug for Sandoz, who only four months ago lost their patent battle to sell generic Cabazitaxel. Given Sanofi’s Jevtana patent doesn’t expire until 2030, there’d be plenty of time to corner the market in the meantime with a less toxic (and maybe more effective) version, that has wider indications than just prostate cancer.

    Come on management, get the deal done.

    https://www.fiercepharma.com/pharma/sanofi-blocks-sandoz-jevtana-generic-patent-win
    Last edited by 1HMac: 18/10/23
 
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Last
9.5¢
Change
0.008(9.20%)
Mkt cap ! $39.14M
Open High Low Value Volume
9.0¢ 9.5¢ 8.8¢ $334.2K 3.710M

Buyers (Bids)

No. Vol. Price($)
2 50354 9.4¢
 

Sellers (Offers)

Price($) Vol. No.
9.5¢ 22908 2
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
SPL (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.